Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CGEM
stocks logo

CGEM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.740
+1.35%
--
--
-0.857
+15.77%
--
--
-0.807
-24.61%
Estimates Revision
The market is revising Downward the revenue expectations for Cullinan Therapeutics, Inc. (CGEM) for FY2025, with the revenue forecasts being adjusted by -13.46% over the past three months. During the same period, the stock price has changed by 51.36%.
Revenue Estimates for FY2025
Revise Downward
down Image
-13.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.05%
In Past 3 Month
Stock Price
Go Up
up Image
+51.36%
In Past 3 Month
Wall Street analysts forecast CGEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEM is 28.60 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast CGEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEM is 28.60 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.580
sliders
Low
23.00
Averages
28.60
High
34.00
Current: 10.580
sliders
Low
23.00
Averages
28.60
High
34.00
BTIG
Julian Harrison
Buy
maintain
$32 -> $38
2025-11-24
Reason
BTIG
Julian Harrison
Price Target
$32 -> $38
2025-11-24
maintain
Buy
Reason
BTIG analyst Julian Harrison raised the firm's price target on Cullinan Therapeutics to $38 from $32 and keeps a Buy rating on the shares. The firm recently caught up with Cullinan management, saying it believes CLN-049 is worth a second look ahead of the company's podium presentation on December 8. The firm added CLN-049 into its model, with a 65% probability of success.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$24 -> $26
2025-11-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24 -> $26
2025-11-20
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Cullinan Therapeutics to $26 from $24 and keeps a Buy rating on the shares Cullinan and partner Taiho Oncology announced they have initiated the rolling submission of a New Drug Application to the FDA seeking accelerated approval of zipalertinib for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum-based systemic chemotherapy. The firm, which expects the rolling NDA submission to be completed by Q1 of 2026, is raising its view of the probability of approval for zipalertinib in EGFR ex20ins mutation-positive NSCLC to 90% from 70%.
H.C. Wainwright
H.C. Wainwright
initiated
$24
2025-08-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24
2025-08-21
initiated
Reason
H.C. Wainwright assumed coverage of Cullinan Therapeutics with a Buy rating and $24 price target. The company has the option to co-commercialize zipalertinib in the U.S. with Taiho and is also eligible to receive an additional $130M in regulatory milestones in connection with the agreement, the analyst tells investors in a research note. The firm sees several near-term catalysts for the shares.
Stifel
Alex Thompson
initiated
$22
2025-06-11
Reason
Stifel
Alex Thompson
Price Target
$22
2025-06-11
initiated
Reason
UBS
David Dai
Buy
downgrade
$30 -> $24
2025-05-12
Reason
UBS
David Dai
Price Target
$30 -> $24
2025-05-12
downgrade
Buy
Reason
UBS analyst David Dai lowered the firm's price target on Cullinan Therapeutics to $24 from $30 and keeps a Buy rating on the shares. Cullinan's key program CLN978 is on track for a data readout in the fourth quarter, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$33
2025-04-16
Reason
HC Wainwright & Co.
Edward White
Price Target
$33
2025-04-16
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cullinan Therapeutics Inc (CGEM.O) is -3.24, compared to its 5-year average forward P/E of -6.65. For a more detailed relative valuation and DCF analysis to assess Cullinan Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.65
Current PE
-3.24
Overvalued PE
2.24
Undervalued PE
-15.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.61
Undervalued EV/EBITDA
-17.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.74
Current PS
0.00
Overvalued PS
100.01
Undervalued PS
-14.53
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CGEM News & Events

Events Timeline

(ET)
2025-12-01
07:18:00
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049
select
2025-11-20 (ET)
2025-11-20
11:05:42
Taiho and Cullinan Therapeutics Begin Rolling Submission of NDA for Zipalertinib
select
2025-11-06 (ET)
2025-11-06
07:08:39
Cullinan Therapeutics Announces Q3 Earnings Per Share of 77 Cents, Below Consensus Estimate of 89 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01NASDAQ.COM
Cullinan Secures FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML

  • FDA Fast Track Designation: Cullinan Therapeutics' CLN-049, a bispecific T cell engager for treating relapsed/refractory acute myeloid leukemia (AML), has received Fast Track Designation from the U.S. FDA, highlighting the urgent need for effective treatments in this area.

  • AML Statistics: Acute myeloid leukemia is the most common acute leukemia in adults, with approximately 22,000 new diagnoses and 11,000 deaths annually in the U.S., and a global impact of 144,000 cases and 130,000 deaths each year.

  • Clinical Trial Results: In Phase 1 trials, CLN-049 showed promising efficacy and safety, including complete responses in heavily pre-treated patients, and is currently being evaluated in two ongoing studies.

  • Future Presentations: Data from the Phase 1 trial will be presented at the 67th American Society of Hematology Annual Meeting on December 8, 2025, as part of the FDA's initiative to expedite the development of therapies for serious conditions.

[object Object]
Preview
9.0
12-01Newsfilter
Cullinan Receives FDA Fast Track Designation for CLN-049 in AML Treatment
  • Fast Track Designation: Cullinan Therapeutics announced that its CLN-049 has received FDA Fast Track designation aimed at providing new treatment options for relapsed/refractory acute myeloid leukemia (AML) patients, highlighting the drug's potential to address unmet medical needs.
  • Clinical Trial Results: Initial Phase 1 trial data shows that CLN-049 demonstrates significant efficacy in heavily pre-treated patients, including complete responses, indicating its broad applicability in treating AML patients with limited effective options.
  • Upcoming Data Presentation: Data from the CLN-049 clinical trial will be presented in an oral session at the 67th American Society of Hematology Annual Meeting on December 8, which is expected to further propel the drug's development and attract investor interest.
  • Strategic Implications: The FDA's Fast Track designation not only accelerates the development timeline for CLN-049 but also provides Cullinan Therapeutics with a crucial competitive edge in the oncology market, underscoring its commitment to innovation in cancer treatment.
[object Object]
Preview
9.0
12-01NASDAQ.COM
Cullinan Therapeutics Receives Fast Track Designation for CLN-049

  • FDA Fast Track Designation: Cullinan Therapeutics has received Fast Track designation from the FDA for CLN-049, aimed at treating relapsed/refractory acute myeloid leukemia.

  • Upcoming Presentation: Data from the Phase 1 clinical trial of CLN-049 will be presented at the 67th American Society of Hematology Annual Meeting on December 8.

  • Company Statement: Jeffrey Jones, Chief Medical Officer, emphasized the significance of this regulatory milestone for advancing treatment options for patients.

  • Market Reaction: Following the announcement, shares of Cullinan Therapeutics increased by 2% in pre-market trading.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cullinan Therapeutics Inc (CGEM) stock price today?

The current price of CGEM is 10.58 USD — it has increased 0.76 % in the last trading day.

arrow icon

What is Cullinan Therapeutics Inc (CGEM)'s business?

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

arrow icon

What is the price predicton of CGEM Stock?

Wall Street analysts forecast CGEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEM is 28.60 USD with a low forecast of 23.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cullinan Therapeutics Inc (CGEM)'s revenue for the last quarter?

Cullinan Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cullinan Therapeutics Inc (CGEM)'s earnings per share (EPS) for the last quarter?

Cullinan Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 22.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cullinan Therapeutics Inc (CGEM)'s fundamentals?

The market is revising Downward the revenue expectations for Cullinan Therapeutics, Inc. (CGEM) for FY2025, with the revenue forecasts being adjusted by -13.46% over the past three months. During the same period, the stock price has changed by 51.36%.
arrow icon

How many employees does Cullinan Therapeutics Inc (CGEM). have?

Cullinan Therapeutics Inc (CGEM) has 111 emplpoyees as of December 05 2025.

arrow icon

What is Cullinan Therapeutics Inc (CGEM) market cap?

Today CGEM has the market capitalization of 624.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free